Here, we investigated the immune response of these subjects using whole-genome cell transcriptomics and serum proteomics and found that nasal Foralumab may dampen CD3+ T effector function by decreasing the GTPases of immunity-associated proteins (GIMAPs) associated pathway Rhoa/ROCK1 and NKG7 gene expression while increasing TGFB1 expression in COVID-19. The gene discussed is TGFB1; the disease is COVID-19.